Home TMU FAQ Sitemap
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Indication
Institution
Department
Principal Investigator
Protocol Title
TMU-JIRB No. Protocol Title Indication Institution Department Principal Investigator Contact
N201801006 Autologous mucosal cell products for repairing defects in the esophagus:process validation for use in clinical research Esophagus:process TMUH Oral Surgery Chia-Yu Wu Hui-Hsin Cheng 02-6620-2589 #15315
Ting Fang 02-6620-2589 #15325
N202005098 Cell function test and cell process validation of autoimmune cell products Cell Therapy TMUH Urology MING-CHE LIU Hui-Hsin Cheng 02-6620-2589 #15315
Ting Fang 02-6620-2589 #15325
N202008042 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated Recurrent Urinary Tract Infections (rUTIs) in Women Urinary Tract Infections TMUH Urology MING-CHE LIU Hui-Hsin Cheng 02-6620-2589 #15315
Ting Fang 02-6620-2589 #15325
N202011014 A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA) Lung Cancer TMUH Pulmonary Medicine Han-Pin Kuo Hui-Hsin Cheng 02-6620-2589 #15315
Ting Fang 02-6620-2589 #15325
N202011029 Establishment of Cell Banks for Placenta- and Umbilical Cord-Derived Stem Cells from Pregnant Women Pregnant Women TMUH Obstetrics Heng-Kien Au Hui-Hsin Cheng 02-6620-2589 #15315
Ting Fang 02-6620-2589 #15325
N202011053 Non-Interventional Collecting Evidences For ILD in Taiwan:Optimized Novel Therapy Interstitial lung disease TMUH Pulmonary Medicine Chi-Li Chung Hui-Hsin Cheng 02-6620-2589 #15315
Ting Fang 02-6620-2589 #15325
N202011055 SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease Breast Cancer TMUH Hematology and Oncology Jia-Ruey Tsai Hui-Hsin Cheng 02-6620-2589 #15315
Ting Fang 02-6620-2589 #15325
N202101003 A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety and Tolerability after Intra-Articular (IA) Injection of UMC119-06-05 in adult subjects with Mild to Moderate Knee Osteoarthritis (KOA) Knee Osteoarthritis (KOA) TMUH Orthopedics Jia-Lin, Wu Hui-Hsin Cheng 02-6620-2589 #15315
Ting Fang 02-6620-2589 #15325
N202104069 Randomized, double-blind, placebo-controlled, parallelgroup Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/Itepekimab (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) Chronic obstructive pulmonary disease (COPD) TMUH Pulmonary Medicine/Sleep Clinic Pai-Chien Chou Hui-Hsin Cheng 02-6620-2589 #15315
Ting Fang 02-6620-2589 #15325
N202104119 SERENA-6: A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor – A ctDNA Guided Early Switch Study Breast Cancer TMUH Hematology and Oncology Jia-Ruey Tsai Hui-Hsin Cheng 02-6620-2589 #15315
Ting Fang 02-6620-2589 #15325
1 2 3 4 5 6 7 8 9 10 13 14 / 14

TOP